Clinical Trials Logo

Thrombosis, Venous clinical trials

View clinical trials related to Thrombosis, Venous.

Filter by:

NCT ID: NCT00911157 Completed - Thrombosis, Venous Clinical Trials

The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Start date: June 2008
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and Deep Vein Thrombosis [DVT])) and safety of GSK576428 as the initial treatment in subjects with acute symptomatic DVT in an open-label design.

NCT ID: NCT00843492 Completed - Thrombosis, Venous Clinical Trials

A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery

FONDACAST
Start date: December 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of fondaparinux in comparison with a heparin (nadroparin) in preventing deep vein thrombosis (blood clots in the leg veins), whether symptomatic or detected by ultrasound, and pulmonary embolism (blood clots that migrate to the lungs) in patients with leg injuries below the knee that require a cast or other type of immobilization but not surgery.

NCT ID: NCT00443053 Completed - Thrombosis, Venous Clinical Trials

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

Start date: March 2007
Phase: Phase 3
Study type: Interventional

To evaluate fondaparinux 2.5mg subcutaneously once daily for 45 days in the treatment of acute (recent) superficial thrombophlebitis.

NCT ID: NCT00320398 Completed - Thrombosis, Venous Clinical Trials

Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

Start date: January 30, 2006
Phase: Phase 3
Study type: Interventional

This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).

NCT ID: NCT00312013 Completed - Thrombosis, Venous Clinical Trials

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

Start date: May 2006
Phase: Phase 3
Study type: Interventional

This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).